Genmab — Januar 2019
-
Nej, det har sikkert ikke noget med den nuværende kursudvikling at gøre, men den har været svag så længe at den er nem at trykke. De forskellige analytikere ved jo godt at med de MAIA data bliver den godkendt, - men så længe det ikke er sket leger de stadig med den.
-
Der sidder vanvittige summer de store kan styre kursen med. De spekulative som køber langsigtet skal have mere sikkerhed langsigtet. Når godkendelse af Maia og sc-versionen er i hus, følger kursen med. Hold hovedet koldt og køb en bedre rødvin. Konsulter eventuelt JV. Han er garant for en god flaske
-
God morgen.
-
MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab https://www.morphosys.com/media-investors/media-center/ad-hoc-morphosys-announces-that-its-patents-were-ruled-invalid-in
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind